November 12 or December 11? Which Hemp Products Lose Legal Status on Which Date

When news broke in early September that the federal hemp ban had been delayed, a lot of people read the headline and stopped. Understandable — but the headline is incomplete in a way that matters, and it is going to catch people out in November.

The delay signed on September 2 did not move one deadline. It created two.

The split, in one sentence

Cannabinoids the cannabis plant can produce naturally got until December 11, 2026. Cannabinoids manufactured by chemical conversion did not get anything, and still lose federal hemp status on November 12, 2026.

Why the language was written that way

Section 2019 of H.R. 6500 postpones the Section 781 restrictions only for cannabinoids "capable of being naturally produced by a Cannabis sativa L. plant." That is a deliberately narrow carve-out, and it reflects where the political consensus actually was.

Converted cannabinoids have been the least popular corner of the hemp industry with regulators for years. They are the products state attorneys general write letters about. Delta-8 in particular has drawn sustained criticism over inconsistent manufacturing, residual reaction chemistry, and packaging that regulators argued appealed to minors. When Congress went looking for something to keep on the original timeline, that was the obvious candidate.

Meanwhile, the products that got the delay are the ones with constituencies: farmers growing plant material, the full-spectrum CBD sector, and hemp beverage companies with meaningful retail distribution.

Which side is your product on?

December 11 — plant-derived

• THCA flower and pre-rolls. THCA is what the plant makes. Straightforwardly covered.
• Hemp-derived delta-9 edibles and beverages. Delta-9 occurs naturally in the plant, so products built on it are covered regardless of whether they are gummies or drinks.
• Live resin and live rosin. Covered if the cannabinoids are extracted from plant material rather than chemically converted. Rosin, which is made with heat and pressure alone, is the cleanest case.
• Full-spectrum CBD. Covered, and separately the subject of explicit White House pressure on Congress to preserve access.

November 12 — converted, no delay

• Delta-8 THC. Occurs in the plant only in trace amounts, far below what any commercial product contains. Essentially all delta-8 on the market is made by acid-catalysed conversion of CBD. Not covered by the delay.
• Delta-10 THC. Same story.
• HHC. Hydrogenated, which is a manufacturing step the plant does not perform. Not covered.
• THC-O acetate. Acetylated in a lab. Not covered, and already the subject of prior DEA correspondence treating it as a controlled substance.
• Converted THCP and similar novel cannabinoids. Not covered where they are synthesized rather than extracted.

The test is process, not molecule. If a cannabinoid exists in the plant but the product's supply is manufactured by conversion, the carve-out language points at how it was made.

Where this gets genuinely murky

We would rather flag the uncertainty than pretend it is clean.

Vapes are the hard case. A vape filled with distillate derived from plant extraction sits on one side. A vape filled with converted delta-8 sits on the other. From the outside, the two are indistinguishable, and the labelling conventions in this category are not good enough to tell them apart reliably. If you use vapes, the COA and the manufacturer's process disclosure are the only things that answer the question.

The FDA has not published the list. Section 781 required the FDA to publish which cannabinoids are covered, and to define "container" for the 0.4 mg cap. That deadline was February 10, 2026. Nothing has been published. The delay did not add a new one. So operators are being asked to classify their own products against a standard the responsible agency has not yet specified.

Neither date is the whole story. Illinois hard-coded November 12 into state law and does not slide to December 11. Texas is already operating on a total-THC standard. Our guide to the states where THCA rules changed in 2026 covers this layer.

What it means for you

If your shelf leans on converted cannabinoids — delta-8 carts, HHC gummies, THC-O anything — your deadline is November 12, and it did not move. The September news does not apply to you, no matter how it was reported.

We do not sell converted cannabinoids and never have. Everything in our aromatic THCA collection is plant-derived California flower, which puts our entire catalog on the December 11 side of the split. Our CBD flower is likewise whole-plant material.

That was a sourcing decision made years before this legislation existed, for quality reasons rather than regulatory ones. It happens to have aged well. If you want the background on how we think about what goes in the catalog, our piece on curation covers it.

What happens on December 11 itself

Worth being clear: December 11 is also the day government funding expires. That is not incidental — the delay was written to land there so the hemp question returns to the floor attached to must-pass legislation. Whether that produces another delay, a permanent framework, or nothing at all is genuinely unknown. We track it on our deadline explainer, which we update when things are signed rather than when they are introduced.

General information, not legal advice. Verify current rules in your jurisdiction before buying or selling. Our products are sold for horticultural and aromatic use only. Statements have not been evaluated by the FDA.